We enrolled 2 patients with MDS and 2 patients with AML (patient characteristics, Table 1) in cohort 1, wherein IFN-γ was administered for 4 weeks as monotherapy prior to the first DLI containing 107 CD3+ cells/kg. This evidence concerns the gene IFNG and acute myeloid leukemia.